<DOC>
	<DOC>NCT00956553</DOC>
	<brief_summary>This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.</brief_summary>
	<brief_title>Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls</brief_title>
	<detailed_description>This study looks at possible cross reactivity between different HPV serotypes and both peripheral antibodies and mucosally-secreted antibodies.</detailed_description>
	<criteria>Aged between 13 and 15 years at the time of the first immunisation Female No contraindications to vaccination as specified in the "Green Book" Immunisation Against Infectious Disease, HMSO. Written informed consent obtained from parent or guardian of subject Pregnant or become pregnant during the course of the trial (no contraindications to vaccination for those taking the contraceptive pill). Breastfeeding mothers Allergic to vaccine components</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HPV</keyword>
	<keyword>Human Papilloma Virus</keyword>
	<keyword>Cervical cancer vaccine</keyword>
</DOC>